Article Listing - As patent cliffs and law suits rule US generic drug industry, research-based majors look to deals and diversification

LOWER SALES/PROFIT FOR BAYER ITALY

6 April 1992

In line with the group's overall international performance, Bayer Italia reports lower sales and profits in 1991. The subsidiary of...

FUTURE PRODUCTS FROM GENETICS INSTITUTE

6 April 1992

Highlighting the most prominent products and product candidates in its commercial development pipeline, Genetics Institute acknowledges that significant progress has...

ASPIRIN HELPS BAYER IN ITALY

6 April 1992

Favorable trends in drugs business and especially good sales of standard products such as aspirin are reported to have helped...

US HOSPITAL FORMULARY GUIDE

6 April 1992

The American Society of Hospital Pharmacists has released guidelines on formulary system management for its members.

The ASHP notes that in...

new swiss hospital costs program

6 April 1992

The Swiss Federal Council has come out in support of the need for severe measures to combat increasing health care...

ARIAD PHARMACEUTICALS STOCK SALE

6 April 1992

The biotechnology concern Ariad Pharmaceuticals of the USA is reported to have raised $46 million in a private stock sale,...

ALLELIX BIOPHARMA: DOUGLAS FROOM

6 April 1992

Douglas Froom has been appointed as vice president for business development at Allelelix Biopharmaceuticals Inc, of Canada.

BAYER DIAGNOSTICS' NEW INSTRUMENT

6 April 1992

Bayer Diagnostics has launched the Ames Clinitek 200+, benchtop, semi-automated urine chemistry analyser for moderate to large volume urine testing....

US MEDICAID REBATES AND "BEST PRICES"

6 April 1992

Eliminating the "best price" provision from the US Medicaid rebate formula for the top 100 single-source and innovator multiple-source drugs...

FUTURE PRODUCTS FROM GENETICS INSTITUTE

6 April 1992

Highlighting the most prominent products and product candidates in its commercial development pipeline, Genetics Institute acknowledges that significant progress has...